Theravance Biopharma (TBPH) Revenue (2013 - 2026)

For the trailing twelve months through Jun 30, 2026, Revenue at Theravance Biopharma was $104.31 million, up 35.1% year-over-year; for FY2025, it came in at $107.46 million, up 66.9% from FY2024.

• Annual Revenue has increased for three consecutive years, with a five-year compound annual growth rate of 8.4% (FY2020 to FY2025).
• In prior years, Theravance Biopharma's Revenue was $64.38 million in FY2024 (+12.1%), $57.42 million in FY2023 (+11.8%), $51.35 million in FY2022 (-7.2%) and $55.31 million in FY2021 (-23.0%).
• Quarterly Revenue has run from a low of $10.42 million in Q1 2023 to a high of $45.89 million in Q4 2025 over five years.
• On a year-over-year basis, Revenue increased in seven of the last eight quarters, with growth averaging 32.7%.
• The strongest year-over-year quarter for Revenue in the past five years was Q4 2025, with growth of 144.7%; the weakest was Q3 2021, with a decline of 27.7%.
• According to Business Quant data, Revenue for the three prior quarters was $17.7 million (Q1 2026), $45.89 million (Q4 2025) and $19.99 million (Q3 2025).